Adipose-and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation

Transplantation

Volumn 99, Issue 9, 2015, Pages 1765-1773

  Plock, Jan A ^a,b,c   Schnider, Jonas T ^a,b   Zhang, Wensheng ^a   Schweizer, Riccardo ^a,b,c   Tsuji, Wakako ^a,b   Kostereva, Nataliya ^a   Fanzio, Paolo M ^a   Ravuri, Sudheer ^a   Solari, Mario G ^a   Cheng, Hui Yun ^d   Rubin, Peter J ^a,b,e   Marra, Kacey G ^a,b,e   Gorantla, Vijay S ^a,b,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e University of Pittsburgh   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL PROLIFERATION; CHIMERA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MALE; MESENCHYMAL STEM CELL; MICROCHIMERISM; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; THERAPY EFFECT; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION; ADIPOSE TISSUE; ANIMAL; BONE MARROW TRANSPLANTATION; BROWN NORWAY RAT; CELL CULTURE; COMPOSITE GRAFT; CYTOLOGY; DRUG ADMINISTRATION; DRUG EFFECTS; HINDLIMB; HISTOCOMPATIBILITY; IMMUNOLOGY; LEWIS RAT; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; SKIN TRANSPLANTATION; TIME; TRANSPLANTATION; TRANSPLANTATION TOLERANCE; VASCULARIZATION;

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADIPOSE TISSUE; ANIMALS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; COMPOSITE TISSUE ALLOGRAFTS; DRUG ADMINISTRATION SCHEDULE; GRAFT SURVIVAL; HINDLIMB; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; RATS, INBRED BN; RATS, INBRED LEW; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

EID: 84947059499     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000731     Document Type: Article

References (53)

1. Khalifian S, Brazio PS, Mohan R, et al. Facial transplantation: the first 9 years. Lancet. 2014;384:2153-2163.
2. Sarhane KA, Tuffaha SH, Broyles JM, et al. A Critical Analysis of Rejection in Vascularized Composite Allotransplantation: Clinical, Cellular and Molecular Aspects, Current Challenges, and Novel Concepts. Front Immunol. 2013; 4:406.
3. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant. 2011;11:808-816.
4. Brandacher G, Lee WP, Schneeberger S. Minimizing immunosuppression in hand transplantation. Expert Rev Clin Immunol. 2012;8:673-683.
5. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg. 2013;257:345-351.
6. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010;12:87-117.
7. Ugarte DA, Morizono K, Elbarbary A, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003;174:101-109.
8. Engela AU, Baan CC, Dor FJ, et al. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol. 2012;3:126.
9. Melief SM, Zwaginga JJ, Fibbe WE, et al. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. 2013; 2:455-463.
10. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLAidentical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389-398.
11. Fouillard L, Francois S, Bouchet S, et al. Innovative cell therapy in the treatment of serious adverse events related to both chemo-radiotherapy protocol and acute myeloid leukemia syndrome: the infusion of mesenchymal stem cells post-treatment reduces hematopoietic toxicity and promotes hematopoietic reconstitution. Curr Pharm Biotechnol. 2013;14:842-848.
12. Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant. 2013;18:51-58.
13. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6:412-422.
14. Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45:1732-1740.
15. BernardoME, Ball LM, Cometa AM, et al. Co-infusion of ex vivo-expanded, parentalMSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2011;46:200-207.
16. Kuo YR, Chen CC, Goto S, et al. Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation. Clin Dev Immunol. 2012;2012:854846.
17. Sucher R, Oberhuber R, Rumberg G, et al. A rapid vascular anastomosis technique for hind-limb transplantation in rats. Plast Reconstr Surg. 2010; 126:869-874.
18. Sacks JM, Kuo YR, Taieb A, et al. Prolongation of composite tissue allograft survival by immature recipient dendritic cells pulsed with donor antigen and transient low-dose immunosuppression. Plast Reconstr Surg. 2008;121:37-49.
19. Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. AmJ Transplant. 2008;8:1396-1400.
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
21. Bochev I, Elmadjian G, Kyurkchiev D, et al. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogenstimulated B-cell immunoglobulin production in vitro. Cell Biol Int. 2008; 32:384-393.
22. Ivanova-Todorova E, Bochev I,Mourdjeva M, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009;126:37-42.
23. Ye Z, Wang Y, Xie HY, et al. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4 + CD25+ regulatory T cells. Hepatobiliary Pancreat Dis. 2008;7:608-614.
24. Wolbank S, Peterbauer A, Fahrner M, et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng. 2007;13:1173-1183.
25. Rider DA, Dombrowski C, Sawyer AA, et al. Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells. Stem Cells. 2008;26:1598-1608.
26. Li H, Zimmerlin L, Marra KG, et al. Adipogenic potential of adipose stem cell subpopulations. Plast Reconstr Surg. 2011;128:663-672.
27. Schipper BM, Marra KG, Zhang W, et al. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg. 2008;60:538-544.
28. Leonard DA, McGrouther DA, Kurtz JM, et al. Tolerance induction strategies in vascularized composite allotransplantation: mixed chimerism and novel developments. Clin Dev Immunol. 2012:863264.
29. Macmillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2009;43:447-454.
30. Ramirez AE, Cheng HY, Lao WW, et al. A novel rat full-thickness hemiabdominal wall/hindlimb osteomyocutaneous combined flap: influence of allograft mass and vascularized bone marrow content on vascularized composite allograft survival. Transpl Int. 2014;27:977-986.
31. Cheng HY, Ghetu N, Huang WC, et al. Syngeneic adipose-derived stem cells with short-term immunosuppression induce vascularized composite allotransplantation tolerance in rats. Cytotherapy. 2014;16: 369-380.
32. Kuo YR, Chen CC, Shih HS, et al. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg. 2011;127:569-579.
33. Cui L, Yin S, Liu W, et al. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng. 2007;13:1185-1195.
34. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.
35. Gonzalez-Rey E, Gonzalez MA, Varela N, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241-248.
36. EliopoulosN, Stagg J, Lejeune L, et al. Allogeneicmarrowstromal cells are immune rejected by MHC class I-and class II-mismatched recipientmice. Blood. 2005;106:4057-4065.
37. Roemeling-van Rhijn M, Reinders ME, Franquesa M, et al. Human allogeneic bone marrow and adipose tissue derived mesenchymal stromal cells induce CD8+ cytotoxic T cell reactivity. J Stem Cell Res Ther. 2013;3:004.
38. Schu S, Nosov M, O'Flynn L, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med. 2012;16:2094-2103.
39. Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 2010;122:2419-2429.
40. Mathes DW, Hwang B, Graves SS, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation. 2011;92:1301-1308.
41. Issa F, Hester J, Goto R, et al. Ex vivo-expanded human regulatory Tcells prevent the rejection of skin allografts in a humanized mouse model. Transplantation. 2010;90:1321-1327.
42. Pilat N, Baranyi U, Klaus C, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant. 2010;10:751-762.
43. Kuo YR, Chen CC, Goto S, et al. Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hindlimb allotransplant model. Plast Reconstr Surg. 2011;128:661e-672e.
44. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation. 2013;95: 169-176.
45. Yamada Y, Ochiai T, Boskovic S, et al. Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Am J Transplant. 2014;14:2704-2712.
46. Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant. 2014; 14:1599-1611.
47. Schlosser S, Dennler C, Eberli D, et al. Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin. Microvasc Res. 2012;83:267-275.
48. Plock JA, Schnider JT, Schweizer R, et al. Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Front Immunol. 2013;4:41.
49. Kuo YR, Goto S, Shih HS, et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation. 2009;87:1769-1777.
50. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297.
51. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683-692.
52. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54-63.
53. Roddy GW, Oh JY, Lee RH, et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells. 2011; 29:1572-1579.